Table 1.
Subject characteristics according to progression and amyloid status
| Characteristic | All subjects (n = 276) | Amyloid negative (n = 116) | Amyloid positive (n = 160) | |||
|---|---|---|---|---|---|---|
| Stable | Progression | Stable | Progression | Stable | Progression | |
| Number of subjects | 154 (56) | 122 (44) | 93 (80) | 23 (20) | 61 (38) | 99 (62) |
| Age (years) | 65.5 ± 7.7 | 68.3 ± 8.1* | 63.8 ± 7.9 | 68.2 ± 8.7† | 68.2 ± 6.5 | 68.3 ± 8.0 |
| Male gender | 97 (63) | 67 (56) | 64 (69) | 16 (70) | 33 (54) | 51 (51) |
| Education | 5.0 ± 1.5 | 4.9 ± 1.7 | 4.8 ± 1.7 | 5.0 ± 1.6 | 5.3 ± 1.2 | 4.9 ± 1.7 |
| MMSE | 27.0 ± 2.2 | 26.1 ± 2.6* | 27.0 ± 2.2 | 26.6 ± 2.5 | 27.0 ± 2.2 | 26.0 ± 2.6† |
| CSF Aβ1–42 | 794 ± 307 | 534 ± 194* | 999 ± 207 | 848 ± 172* | 481 ± 104 | 462 ± 107 |
| WMH (Fazekas) | 0.99 ± 0.92 | 1.03 ± 0.80 | 0.88 ± 0.93 | 1.30 ± 1.02 | 1.15 ± 0.89 | 0.97 ± 0.73 |
| NGMV | 0.41 ± 0.04 | 0.39 ± 0.05* | 0.42 ± 0.04 | 0.39 ± 0.06* | 0.41 ± 0.04 | 0.39 ± 0.04† |
| Follow-up (years) | 2.5 ± 1.5 | 2.6 ± 1.7 | 2.3 ± 1.4 | 2.8 ± 2.0 | 2.7 ± 1.7 | 2.6 ± 1.3 |
| Follow-up diagnosis | ||||||
| AD | – | 104 (85) | – | 10 (43) | – | 94 (95) |
| DLB | – | 3 (2) | – | 2 (9) | – | 1 (1) |
| FTD | – | 4 (3) | – | 3 (13) | – | 1 (1) |
| VaD and mixed | – | 9 (7) | – | 6 (26) | – | 3 (3) |
| Other | – | 2 (2) | – | 2 (9) | – | 0 (0) |
Data presented as mean ± SD or count (%)
AD Alzheimer’s disease, CSF cerebrospinal fluid, DLB Lewy body dementia, FTD fronto-temporal dementia, MMSE Mini-Mental state examination, NGMV normalized gray matter volume, VaD vascular dementia, WMH white matter hyperintensities measured with 4-point Fazekas scale
*p < 0.01 different from stable subjects
† p < 0.05 different from stable subjects